Surfactant protein D is associated with pulmonary manifestations of chronic graft-versus-host disease following hematopoietic stem cell transplantation
Research output: Contribution to journal › Comment/debate › Research › peer-review
Standard
Surfactant protein D is associated with pulmonary manifestations of chronic graft-versus-host disease following hematopoietic stem cell transplantation. / Krarup, Anne Mols; Kielsen, Katrine; Uhlving, Hilde Hylland; Steffensen, Rudi; Sørum, Maria Ebbesen; Nielsen, Kim Gjerum; Buchvald, Frederik F.; Sorensen, Grith L.; Müller, Klaus Gottlob.
In: Pediatric Pulmonology, Vol. 59, No. 4, 2024, p. 1103-1107.Research output: Contribution to journal › Comment/debate › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Surfactant protein D is associated with pulmonary manifestations of chronic graft-versus-host disease following hematopoietic stem cell transplantation
AU - Krarup, Anne Mols
AU - Kielsen, Katrine
AU - Uhlving, Hilde Hylland
AU - Steffensen, Rudi
AU - Sørum, Maria Ebbesen
AU - Nielsen, Kim Gjerum
AU - Buchvald, Frederik F.
AU - Sorensen, Grith L.
AU - Müller, Klaus Gottlob
N1 - Funding Information: This study was supported by The Danish Cancer Society. The authors alone are responsible for the content and writing of the paper.
PY - 2024
Y1 - 2024
N2 - Impairment of pulmonary function is reported in around 60% of children after allogeneic hematopoietic stem cell transplantation (HSCT), used as a treatment of high-risk acute leukemias and severe hematological disorders.1 The decline in pulmonary function is transient in most patients, but 5%–10% of children undergoing HSCT develop bronchiolitis obliterans (BO), which is a severe manifestation of chronic graft-versus-host disease (cGvHD). This progressive obstructive airway disease has a 5-year mortality rate of 33%–55% and may lead to permanent severe disability in a large proportion of those who survive.2 While early diagnosis and immunosuppressive treatment of BO may improve the prognosis, initial symptoms are often mild, and regular monitoring with spirometry is therefore important in the follow-up after HSCT. Importantly, however, young children below 5 years of age cannot cooperate to spirometry and reliable measurements may be hard to obtain even in older patients. Therefore, early predictive biomarkers of pulmonary GvHD are highly needed to guide clinical decisions.
AB - Impairment of pulmonary function is reported in around 60% of children after allogeneic hematopoietic stem cell transplantation (HSCT), used as a treatment of high-risk acute leukemias and severe hematological disorders.1 The decline in pulmonary function is transient in most patients, but 5%–10% of children undergoing HSCT develop bronchiolitis obliterans (BO), which is a severe manifestation of chronic graft-versus-host disease (cGvHD). This progressive obstructive airway disease has a 5-year mortality rate of 33%–55% and may lead to permanent severe disability in a large proportion of those who survive.2 While early diagnosis and immunosuppressive treatment of BO may improve the prognosis, initial symptoms are often mild, and regular monitoring with spirometry is therefore important in the follow-up after HSCT. Importantly, however, young children below 5 years of age cannot cooperate to spirometry and reliable measurements may be hard to obtain even in older patients. Therefore, early predictive biomarkers of pulmonary GvHD are highly needed to guide clinical decisions.
KW - bronchiolitis obliterans
KW - graft-versus-host disease
KW - hematopoietic stem cell transplantation
KW - Surfactant protein D
U2 - 10.1002/ppul.26836
DO - 10.1002/ppul.26836
M3 - Comment/debate
C2 - 38206069
AN - SCOPUS:85181883583
VL - 59
SP - 1103
EP - 1107
JO - Pediatric pulmonology. Supplement
JF - Pediatric pulmonology. Supplement
SN - 1054-187X
IS - 4
ER -
ID: 379706733